Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.72 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.71 |
| ▸ | ADRB3 | P13945 | 13/20 | 0.71 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511171 | 1.00 | ADRB2 (0.72) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL775235 | 0.89 | ADRB2 (0.82) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL27667798 | 0.89 | ADRB2 (0.82) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL4509509 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL4509515 | 0.89 | ADRB2 (0.71) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL5708324 | 0.88 | ADRB2 (0.80) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL776635 | 0.85 | ADRB2 (0.80) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL3838704 | 0.84 | ADRB2 (0.85) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL27667945 | 0.84 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CHRM2 | |
| SCHEMBL776967 | 0.84 | ADRB2 (0.76) | ADRB2ADRB1ADRB3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566785-B2 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. (US) | 2009-07-28 | — | — | US | claimed |
| US-20060058530-A1 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. | 2006-03-16 | — | — | US | claimed |
| US-7566785-B2 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| EP-1786762-A2 | AMIDINE SUBSTITUTED ARYL ANILINE COMPOUNDS | Theravance, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006031556-A2 | AMIDINE SUBSTITUTED ARYL ANILINE COMPOUNDS | THERAVANCE. INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| US-20060058530-A1 | Amidine substituted aryl aniline compounds | THERAVANCE, INC. | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058530-A1 | Amidine substituted aryl aniline compounds | ADRB2, ADRB1, ADRB3 | ADRB2 1/4885ADRB1 2/4885ADRB3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.